Cellestia Biotech, specialized in targeting Transcription Factors (TFs) involved in human diseases, is initiating a new drug discovery program focused on TFs. The programme, which addresses unmet medical needs in cancer, autoimmune and inflammatory disorders (AIIDs), is launched in collaboration with Vincent Zoete from the Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, Lausanne and SIB. The programme is co-financed by Innosuisse.

“We look forward to working with Cellestia in its development of this class of TF inhibitors, which holds exciting promise for therapeutic targeting of cancer and several human diseases”, say Vincent Zoete, Group Leader, and Antoine Daina, Senior Research Scientist at SIB.

Read more about the programme >>